Khanlari B, Buser A, Lugli A, Tichelli André, Dirnhofer S
Institute of Pathology, University Hospital Basel, Schoenbeinstrasse 40, 4031 Basel, Switzerland.
Leuk Lymphoma. 2003 Dec;44(12):2055-9. doi: 10.1080/1042819031000119307.
In hematological neoplasms CD56 (N-CAM) is expressed by T/natural killer (NK) cell lymphoma, by most neoplastic plasma cells in multiple myeloma and also in a subset of acute myelogenous leukemias (AML). In the latter, it is an indicator of poor clinical outcome. Most of the data on CD56 expression in acute leukemia have been obtained by flow cytometric analysis. Up to now, no systematic analysis of the expression pattern of CD56 in formalin fixed paraffin embedded bone marrow biopsies of acute leukemias has been performed. We immunohistochemically studied the expression of CD56 in a series of 141 bone marrow biopsies fixed in Sublimat Mercury II Chloride (SUSA) including 100 cases of AML FAB M0-M7, 11 cases of AML not further specified, 3 cases of biphenotypical leukemia, 20 cases of acute lymphoblastic leukemia (ALL) and 7 cases of reactive bone marrow biopsies. Overall, 14 of 134 (10%) leukemia cases were positive for CD56. Detail analysis revealed positivity in 5/13 cases of AML M5 (38%), 3/9 AML M1 (33%), 1/8 AML M0 (13%), 1/11 AML not specified (9%), 2/31 AML M2 (7%) and 2/26 AML M4 (8%). All cases of ALL and biphenotypic leukemias were CD56 negative. The CD56 expression in AML M5 was statistically significant (p = 0.003). On paraffin embedded bone marrow biopsies CD56 expression occurs in de novo AML with an overall frequency of 13%. It is significantly correlated with AML M5, which is positive in 38% of the cases. Cases of ALL are consistently CD56 negative.
在血液系统肿瘤中，CD56（神经细胞黏附分子）在T/自然杀伤（NK）细胞淋巴瘤、多发性骨髓瘤中的大多数肿瘤性浆细胞以及一部分急性髓系白血病（AML）中表达。在后者中，它是临床预后不良的一个指标。关于急性白血病中CD56表达的大多数数据是通过流式细胞术分析获得的。到目前为止，尚未对急性白血病福尔马林固定石蜡包埋骨髓活检中CD56的表达模式进行系统分析。我们采用免疫组织化学方法研究了141例用二氯化汞（SUSA）固定的骨髓活检组织中CD56的表达，其中包括100例AML FAB M0 - M7、11例未进一步分类的AML、3例双表型白血病、20例急性淋巴细胞白血病（ALL）以及7例反应性骨髓活检组织。总体而言，134例白血病病例中有14例（10%）CD56呈阳性。详细分析显示，AML M5的13例中有5例（38%）呈阳性，AML M1的9例中有3例（33%）呈阳性，AML M0的8例中有1例（13%）呈阳性，11例未分类的AML中有1例（9%）呈阳性，AML M2的31例中有2例（7%）呈阳性，AML M4的26例中有2例（8%）呈阳性。所有ALL和双表型白血病病例CD56均为阴性。AML M5中的CD56表达具有统计学意义（p = 0.003）。在石蜡包埋的骨髓活检组织中，CD56表达出现在初发AML中，总体频率为13%。它与AML M5显著相关，AML M5中38%的病例呈阳性。ALL病例始终CD56阴性。
